目的 觀察面癱Ⅰ號(hào)方配合康復(fù)訓(xùn)練治療周圍性面癱的臨床療效。方法 選取2011年12月-2013年12月山東省交通醫(yī)院就診的周圍性面癱患者102例，隨機(jī)分為治療組（51例）和對(duì)照組（51例）。對(duì)照組患者進(jìn)行康復(fù)訓(xùn)練，20 min/次，2次/d。治療組在對(duì)照組基礎(chǔ)上口服面癱Ⅰ號(hào)方，100 mL/次，早、晚2次服用。兩組均持續(xù)治療3周。觀察兩組的臨床療效，同時(shí)比較瞬目反射R1波潛伏期和面神經(jīng)電圖復(fù)合動(dòng)作電位波幅損失百分比治療前后的變化。結(jié)果 治療組和對(duì)照組的總有效率分別為92.16%、84.31%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者的瞬目反射R1波潛伏期均較治療前明顯縮短，同組治療前后差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；治療后，治療組的R1波潛伏期明顯短于對(duì)照組，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，治療組支配眼輪匝肌、鼻肌以及口輪匝肌的神經(jīng)波幅損失百分比較治療前明顯下降，治療前后差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；對(duì)照組支配眼輪匝肌和鼻肌的波幅損失百分比較治療前明顯下降，治療前后差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；治療后，治療組鼻肌、口輪匝肌的神經(jīng)波幅損失百分比明顯低于對(duì)照組，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 面癱Ⅰ號(hào)方聯(lián)合康復(fù)訓(xùn)練治療周圍性面癱有較好的臨床療效，可有效改善面神經(jīng)功能，值得臨床推廣應(yīng)用。

Objective To observe the clinical efficacy of Miantan No.1 Prescription combined with rehabilitation training in the treatment of peripheral facial paralysis. Methods The patients (102 cases) with peripheral facial paralysis in Shandong Jiaotong Hospital from December 2011 to December 2013 were randomly divided into treatment (51 cases) and control (51 cases) groups. The patients in the control group were accepted rehabilitation training, 20 min/time, twice daily; The patients in the treatment group were given Miantan No.1 Prescription, 100 mL/time, twice in the morning and at night daily. All the patients were treated continuously for 3 weeks. The total clinical efficacy was observed, including the changes of blink reflex R1 wave incubation period and loss percentage of facial nerve compound action potential amplitude power before and after the treatment. Results The total effective rates of the patients in the treatment and control groups were 92.16% and 84.31%, respectively, with significant difference between the two groups (P < 0.05). After the treatment, blink reflex R1 wave incubation period was shorter than that before the treatment in the two groups, and the differences was statically significant in the same group before and after treatment (P < 0.05). Treatment group was shorter than that of the control group, with significant difference between the two groups (P < 0.05). After the treatment, the nerve comamplitude loss percentage of orbicularis oculi muscle, nose and mouth muscle in the treatment group was significantly decreased, and the difference was statistically significant before and after the treatment (P < 0.05). Nerve amplitude loss percentage of orbicularis oculi muscle and nose muscle in the control group was significantly decreased, and the difference was statistically significant before and after the treatment (P < 0.05). After the treatment, the nerve amplitude loss percentage of nose and mouth muscle in the treatment group was lower than those in the control group, with the significant difference between the two groups (P < 0.05). Conclusion Miantan No.1 Prescription combined with rehabilitation training has a good clinical efficacy in the treatment of peripheral facial paralysis, and can effectively improve the function of facial nerve, which is worthy of clinical application.